Founder

Paul Sieving, MD, PhD, is Professor of Ophthalmology at the UC Davis. He is recognized internationally for his expertise in clinical conditions of genetic retinal and macular degeneration.

Dr. Sieving’s research focuses on working with patients who have genetic retinal diseases and on developing laboratory approaches to repairing injured retinal cells and tissues. He works to understand eye diseases toward developing therapies for inherited retinal dystrophies. He established the Center for Ocular Regenerative Therapy (CORT) at UC Davis Health in 2020. CORT physicians and scientists are developing gene and stem cell therapies for these conditions. He currently is conducting a human gene therapy clinical trial for X-Linked Retinoschisis (XLRS) disease. Dr. Sieving holds elected membership in the National Academy of Medicine USA, in 2006, and in the German Academy of Science in 2013. He has published more than 250 scientific papers and book chapters. He previously was Director of the National Eye Institute at NIH.